- Home
- CYD vs MYGN Comparison
CYD vs MYGN Comparison
Compare CYD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- MYGN
- Stock Information
- Founded
- CYD 1951
- MYGN 1991
- Country
- CYD Singapore
- MYGN United States
- Employees
- CYD N/A
- MYGN N/A
- Industry
- CYD Industrial Machinery/Components
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CYD Industrials
- MYGN Health Care
- Exchange
- CYD Nasdaq
- MYGN Nasdaq
- Market Cap
- CYD 609.7M
- MYGN 642.0M
- IPO Year
- CYD 1994
- MYGN 1995
- Fundamental
- Price
- CYD $38.24
- MYGN $7.55
- Analyst Decision
- CYD
- MYGN Hold
- Analyst Count
- CYD 0
- MYGN 13
- Target Price
- CYD N/A
- MYGN $13.50
- AVG Volume (30 Days)
- CYD 267.4K
- MYGN 1.3M
- Earning Date
- CYD 08-08-2025
- MYGN 11-06-2025
- Dividend Yield
- CYD 1.29%
- MYGN N/A
- EPS Growth
- CYD 40.10
- MYGN N/A
- EPS
- CYD 1.66
- MYGN N/A
- Revenue
- CYD $3,159,401,156.00
- MYGN $832,900,000.00
- Revenue This Year
- CYD $6.43
- MYGN $0.17
- Revenue Next Year
- CYD $11.20
- MYGN $6.19
- P/E Ratio
- CYD $24.31
- MYGN N/A
- Revenue Growth
- CYD 17.99
- MYGN 3.83
- 52 Week Low
- CYD $8.61
- MYGN $3.76
- 52 Week High
- CYD $41.39
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CYD 70.10
- MYGN 67.36
- Support Level
- CYD $32.71
- MYGN $7.13
- Resistance Level
- CYD $33.87
- MYGN $7.69
- Average True Range (ATR)
- CYD 1.74
- MYGN 0.43
- MACD
- CYD 0.30
- MYGN 0.03
- Stochastic Oscillator
- CYD 73.70
- MYGN 82.08
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.